Overview

A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Kowa Company, Ltd.